文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

KIR 有利型 TCR-αβ/CD19 去除单倍体造血细胞移植治疗儿童 ALL/AML/MDS:PTCTC ONC1401 试验主要分析

KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.
PubMed 文献 · Blood · 2022-01-01

这项前瞻性多中心研究纳入 51 例 0.7 至 21 岁急性白血病或 MDS 患儿,接受 KIR 有利型 TCR-αβ/CD19 去除单倍体移植,1 年无病生存率为 78%。多因素分析显示与其他供者来源相比 DFS 和 OS 相似,但 2 至 4 级和 3 至 4 级急性 GVHD、慢性 GVHD 及移植相关死亡风险明显降低。

要点

  • KIR 有利型 TCR-αβ/CD19 去除单倍体移植 1 年无病生存率为 78%。
  • 与其他供者来源相比 DFS 和 OS 相似,但急慢性 GVHD 及移植相关死亡风险明显降低。
  • 小于 10 岁、采用降低毒性预处理及移植前 MRD<0.01% 者 2 年 DFS 和 OS 更优。

核心结论

  • 这项前瞻性多中心研究显示,采用降低毒性预处理的 TCR-αβ/CD19 去除单倍体供者移植可改善儿童急性白血病和 MDS 的结局。
  • 作者认为需要开展将这一方法与相合无关供者进行比较的随机试验。

研究设计与样本

  • 前瞻性多中心研究,纳入 51 例 0.7 至 21 岁急性白血病或 MDS 患儿,供者依据配体错配和/或高 B 含量判定为 KIR 有利型。
  • 比较 KIR 有利型单倍体移植队列与其他供者细胞来源受者的 2 年结局。
  • 试验在 ClinicalTrials.gov 注册号为 NCT02646839。

主要发现

  • 1 年无病生存率为 78%。
  • 小于 10 岁、接受降低毒性预处理而非清髓性预处理、以及移植前微小残留病<0.01% 的患儿 2 年 DFS 和 OS 更优。
  • 多因素分析显示 KIR 有利型单倍体队列与其他供者细胞来源相比 DFS 和 OS 相似。
  • 多因素分析显示与其他供者细胞来源相比,2 至 4 级和 3 至 4 级急性 GVHD、慢性 GVHD 及移植相关死亡风险明显降低。
  • 少数族裔和种族占入组患者的 53%,大型受者/供者队列 KIR 筛查数据显示按本研究定义超过 80% 的受者有 KIR 有利型供者。

局限性

  • 作者认为需要开展将这一方法与相合无关供者进行比较的随机试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed a prospective multicenter study of T-cell receptor αβ (TCR-αβ)/CD19-depleted haploidentical hematopoietic cell transplantation (HCT) in children with acute leukemia and myelodysplastic syndrome (MDS), to determine 1-year disease-free survival (DFS) and compare 2-year outcomes with recipients of other donor cell sources. Fifty-one patients aged 0.7 to 21 years were enrolled; donors were killer immunoglobulin-like receptor (KIR) favorable based on ligand mismatch and/or high B content. The 1-year DFS was 78%. Superior 2-year DFS and overall survival (OS) were noted in patients <10 years of age, those treated with reduced toxicity conditioning (RTC) rather than myeloablative conditioning, and children with minimal residual disease <0.01% before HCT. Multivariate analysis comparing the KIR-favorable haploidentical cohort with controls showed similar DFS and OS compared with other donor cell sources. Multivariate analysis also showed a marked decrease in the risk of grades 2 to 4 and 3 to 4 acute graft versus host disease (aGVHD), chronic GVHD, and transplant-related mortality vs other donor cell sources. Ethnic and racial minorities accounted for 53% of enrolled patients, and data from a large cohort of recipients/donors screened for KIR showed that >80% of recipients had a KIR-favorable donor by our definition, demonstrating that this approach is broadly applicable to groups often unable to find donors. This prospective, multicenter study showed improved outcomes using TCR-αβ/CD19-depleted haploidentical donors using RTC for children with acute leukemia and MDS. Randomized trials comparing this approach with matched unrelated donors are warranted. This trial was registered at https://clinicaltrials.gov as #NCT02646839.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pulsipher MA, Ahn KW, Bunin NJ, et al. KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. Blood. 2022. PMID: 35776909. doi:10.1182/blood.2022015959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。